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A patient with recessive epidermolysis bullosa sim-
plex due to a previously described homozygous
KRT14 1842±2A®C splice-site mutation was re-
examined, because we unexpectedly found signs of
revertant mosaicism. The germline mutation resulted
in different aberrant transcripts containing premature
termination codons, all leading to truncated keratin
14 proteins. Basal keratinocytes in skin and in culture
completely lacked keratin 14 and intermediate ®la-
ments. From this keratin 14±/± patient we started
cultures from a new skin biopsy and here, we seren-
dipitously found keratinocytes that spontaneously
expressed keratin 14. This biopsy had been taken
from an area of skin that was clinically affected,
because blisters could simply be evoked by gentle
rubbing. Immuno¯uorescence and electron micro-
scopy of additional biopsies from this skin area
revealed a mosaic expression of keratin 14 and
reappearance of intermediate ®laments in basal kera-
tinocytes. Immunoblotting showed a revertant kera-
tin 14 polypeptide with seemingly normal molecular
weight. DNA analysis of exon 2 and its ¯anking
intron borders showed no additional mutations in
the genomic KRT14 sequence. Analysis of mRNA
isolated from mosaic skin keratinocytes revealed an
additional in-frame transcript (1844T®G, 1845D6)
that codes for an abnormal keratin 14 polypeptide
with a two residue deletion and one amino acid
change. The re-expression of a revertant, albeit
abnormal, keratin 14 polypeptide, so-called partial
revertant mosaicism, accounts for the antibody stain-
ing pattern and for the reappearance of intermediate
®laments, which however, are semifunctional and
not able to revert the clinical phenotype. The com-
bination of a keratin 14-positive and a keratin 14-
negative cell population in epidermis as well as in
cultured keratinocytes suggests that the cellular
reversion might be caused by an endogenous factor.
We hypothesize that a second somatic modulating
factor in the genome that affects the processing of
the mutant KRT14 pre-mRNA may underlie this
phenomenon. Key words: cytoskeleton/gene reversion/
mosaicism/tono®laments. J Invest Dermatol 118:626±630,
2002
R
evertant mosaicism in skin is a new genetic principle
that has been discovered recently (Jonkman et al,
1997), for review (Jonkman, 1999). A revertant is a
mutant that has regained, partially or completely,
the wild-type phenotype by either genetic or
nongenetic mechanism of reversion (Rieger et al, 1996). Partial
revertant mosaicism is a phenomenon in which the reversion is
partial, for instance, in which the revertant protein is immunohis-
tochemical reactive, but does not function, thus not leading to
clinical improvement.
In this study we report a patient with keratin 14 (K14)±/±
recessive epidermolysis bullosa simplex (REBS) who was a partial
revertant mosaic. During gene correction experiments (Van der
Steege et al, 2001) we serendipitously found keratinocytes that
spontaneously expressed K14 in cell cultures derived from the
K14±/± patient. Upon immuno¯uorescence examination of a new
skin biopsy, K14 appeared to be present in the epidermis in a
mosaic pattern. In an attempt to disclose the underlying cause of
this revertant mosaicism, the patient was re-examined clinically,
and the keratinocytes from revertant and mutant skin were analyzed
at the DNA, RNA, and protein level.
MATERIAL AND METHODS
Patient characteristics and skin biopsies The patient was a female,
age 67 y, suffering from REBS, previously reported by us as patient III-2
(Jonkman et al, 1996). On the genomic DNA level, a homozygous
KRT14: 1842±2A®C transition was detected, situated in the acceptor
splice site of intron 1. In the initial study, two aberrant mRNA transcripts
generated by this mutation were detected, including one with complete
skipping of exon 2, and one containing a deletion of the ®rst 10 bp of
exon 2 (Jonkman et al, 1996). This null mutation resulted in the complete
ablation of K14 and of tono®laments in basal cells. The revertant
keratinocytes described in this study originated from a biopsy of the lower
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right arm of the patient. Two more biopsies were taken from K14-
negative skin on the trunk. In addition we re-examined the skin biopsies
of other affected individuals of this family and of two unrelated REBS
patients with the same mutation (Hut et al, 2000).
Keratinocytes were harvested from biopsies taken from the revertant
and mutant skin, and cultured under serum-free conditions. A skin
biopsy sample of an unaffected individual was included for reference.
Immuno¯uorescence microscopy For immuno¯uorescence
microscopy on tissue samples, un®xed cryostat sections of snap frozen
skin biopsies were processed as previously described (Jonkman et al,
1996). K14 was stained with monoclonal antibodies LL001 and LL002
(kind gift of Prof. B. Lane, Dundee) directed against the carboxy-
terminal tail of the protein (Purkis et al, 1999). K5 + 8 was stained with
monoclonal antibody RCK102 (kind gift of Dr. F.C.S. Ramaekers,
Maastricht). As a secondary step we used Alexa488-conjugated goat anti-
mouse IgG (Molecular Probes, Eugene, OR).
For immuno¯uorescence on cultured keratinocytes, cells were grown
on glass coverslips, washed with phosphate-buffered saline (PBS) and
®xed for 10 min with 1% formaldehyde in PBS. Cells were permeabi-
lized by incubation in 0.5% Triton X-100 in PBS for 5 min, followed
by blocking with 1% (wt/vol) bovine serum albumin in PBS for 20 min
at 37°C. Subsequent incubation with primary antibody was carried out
for 45 min at 37°C. The cells were rinsed three times with PBS and
incubated with Alexa488-labeled goat anti-mouse IgG for 30 min at
room temperature. Finally, the nuclei were stained blue with bisbenza-
mide.
Electron microscopy was performed as described previously (Jonkman
et al, 1996).
Immunoblotting Preparation of cell extracts and immunoblotting was
as described before (Pas et al, 1995). K14-speci®c monoclonal antibody
was LL002. Bound antibody was detected by subsequent incubation with
goat anti-mouse IgG followed by alkaline phosphatase-conjugated rabbit
anti-goat IgG.
Mutation analysis DNA was isolated from primary keratinocytes by
high salt/chloroform extraction (Miller et al, 1988). Prior to polymerase
chain reaction (PCR) ampli®cation of KRT14 exon 2, the DNA was
digested with AluI in order to prevent coampli®cation of the highly
homologous KRT14 pseudogene (Savtchenko et al, 1988) as described
previously (Hut et al, 2000). After ampli®cation the PCR products were
puri®ed using the high pure PCR product puri®cation kit (Boehringer
Mannheim, Basel, Switzerland), and sequenced by automated DNA
sequencing (ABI 377, Perkin Elmer, Norwalk, CT).
Haplotyping To investigate if the patient had inherited KRT14 alleles
that were identical by descent to the KRT14 alleles carrying the KRT14:
1842±2A®C splice site mutation of the previously described REBS
patients (Jonkman et al, 1996; Hut et al, 2000), three microsatellite
markers were analyzed ¯anking the KRT14 locus, namely D17S800,
D17S1814, and D17S1851. KRT14 is located between D17S800 and
D17S1818 (Genemap 1999, http://www.ncbi.nlm.nih.gov/genemap/).
D17S1814 genetically maps to the same position as D17S1818.
Therefore, we conclude that the most likely order of these loci is
D17S800±KRT14±D17S1814±D17S1851. DNA was extracted from
peripheral blood by the high salt/chloroform extraction method. To
amplify the particular sequences, the following PCR program was used:
denaturation at 94°C for 1 min, annealing at 56°C (D17S800 and
D17S1851) or 62°C (D17S1814) for 1 min, and extension at 72°C for
1 min (30 cycles). All forward primers were ¯uorescein labeled. The
lengths of the PCR products were determined using an automated
sequencer (ALF, Amersham Pharmacia, Biotech AB, Uppsala, Sweden).
Analysis of RNA splice variants RNA was extracted from
keratinocyte cultures by the RNeasy Mini Kit (QIAGEN Genomics
Inc., Bothell, Washington). The Ready-To-Go You-Prime First-Strand
Beads (Amersham Pharmacia Biotech AB, Uppsala, Sweden) and random
primers were used for the synthesis of ®rst-strand cDNA. After cDNA
synthesis, a reverse transcription±PCR was carried out with the forward
primer 5¢-GAGAAGGTGACCATGCAGAA-3¢ and the reverse primer
5¢-ACATTGACATCTCCACCCAC-3¢ (nucleotide positions 403±
3022). For each sample 10 ml cDNA, 10 ml reaction buffer (with a ®nal
concentration of 10 mM Tris±HCl pH 9, 1.5 mM MgCl2, 50 mM KCl,
0.01% wt/vol gelatin and 0.1% vol/vol Triton X-100), 40 pmol forward
primer, 40 pmol reverse primer, and 2.5 units rTaq polymerase
(Pharmacia Biotech, Piscataway, NJ) were used in a total volume of
100 ml. The amplicons were inserted into the pCRII cloning vector
(Invitrogen, San Diego, CA) and transformed to Escherichia coli strain
INVaF¢. After spreading the culture on to NZYM plates containing
ampicillin and X-gal, several white colonies of each sample were
cultured, plasmids were isolated and subjected to direct sequencing using
an automated DNA sequencer (ABI 377, Perkin Elmer).
RESULTS
Clinical phenotype was not reverted The skin of the patient
was generalized affected; after meticulous inspection we could not
®nd any areas of skin with signs of clinical reversion (Fig 1).
Cellular phenotype was reverted Immuno¯uorescence
analysis of cultured keratinocytes derived from the right lower
arm revealed a mixture of K14-positive and K14-negative
keratinocytes (Fig 2A), whereas in skin biopsies from other areas
only K14-negative cells could be detected. Immuno¯uorescence
analysis of a skin biopsy from the same area revealed an epidermis
with a mosaic K14 pattern with clusters of K14-negative and K14-
positive keratinocytes (Fig 2B). The epidermal staining pattern of
K5 was normal and was not altered by K14 mosaicism (data not
shown).
Figure 1. Erosion could easily be evoked on revertant skin. The
skin of the right lower arm after rubbing with the eraser of a pencil. The
scar of the previous biopsy is visible in the upper right corner.
Figure 2. Mosaic expression of K14 in keratinocyte culture and in
epidermis. (A) Keratinocyte culture; (B) epidermis.
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Electron microscopy showed reduced reappearance of tono®la-
ments in basal cells of revertant skin (Fig 3). The revertant
tono®lament bundles were abnormally packed similar as in
dominant EBS KoÈbner.
By immunoblot analysis, the production of K14 molecules
appeared to be partially restored in revertant keratinocytes (Fig 4).
The revertant K14 molecules apparently had the same mobility as
wild-type K14 of » 50 kDa.
Revertant and mutant keratinocytes were genetically similar
at the KRT14 locus Both negative and revertant keratinocytes
contained the original KRT14: 1842±2A®C splice-site mutation
at the junction of intron 1 and exon 2 (Hut et al, 2000). No
additional mutation in exon 2 and its ¯anking intron borders was
identi®ed in the genomic KRT14 sequence.
Haplotype analysis of the chromosomal region 17q harboring the
KRT14 locus in the REBS patients demonstrated that all three
affected family members were homozygous for the analyzed
polymorphic markers. When the data of the two other, unrelated,
REBS patients were included, we found that at least for D17S800
all mutant alleles were identical, whereas one allele differed in
D17S1814, and two alleles differed in the more distant marker.
This may indicate that the 1842±2A®C mutation has originally
occurred on a (1,1,1) haplotype causing a founder effect in the
Dutch population, and during subsequent meioses the shared
segment from this haplotype has become smaller in some
chromosomes of more distantly related patients (Table I).
Only revertant keratinocytes produced an aberrant in-frame
KRT14 transcript RNA analysis of mutant keratinocytes
showed the two initially described non-sense RNA splice
variants: one with skipping of exon 2 and a second one
containing a 10 bp deletion. The revertant keratinocytes,
however, contained the 10 bp deletion transcript and in addition
a transcript harboring a 6 bp deletion in combination with a U to a
G change (Table II). In contrast with the other transcripts, this
D6 bp transcript did have an intact reading frame. We unexpectedly
also found an additional transcript, which we traced back to the
K14 pseudogene. This transcript was found in mutant and revertant
keratinocytes of the patient, but not in wild-type keratinocytes of a
normal individual (sequence data not shown).
DISCUSSION
In this study we describe a patient with the typical clinical features
of REBS. Although this patient, at the genomic level, only had the
homozygous splice site mutation 1842±2A®C, her skin had areas
with, clinically unnoticeable, mosaic K14 expression.
Analysis of the KRT14 transcripts in the K14-positive cells
revealed the presence of an additional mRNA splice variant. This
splice variant is characterized by an in-frame deletion of 6 bp and a
Figure 3. Tono®laments were expressed in revertant basal keratinocytes. Tono®lament bundles (arrows) were re-expressed, although reduced,
in basal cells of revertant skin (A, overview, and B, detail). Panels C and D show desmosomes between basal (BC) and suprabasal cells (SBC). In mutant
skin (C) the tono®laments were lacking in the basal cell, whereas in revertant skin (D) a reduced amount of tono®laments inserted into the
desmosome.
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transversion of a U to a G both at the beginning of exon 2, whereas
the other detected splice variants, Dexon 2 and D10 bp, led to an
out-of-frame sequence. The in-frame splice variant results in a
slightly altered K14 polypeptide with one amino acid substitution
and a deletion of two amino acids. The in-frame skip was located at
the beginning of the 1B helical rod domain (Fig 5) and will
undoubtedly affect normal winding of the keratin a-helix.
The limited re-expression of aberrant K14 polypeptides in
revertant keratinocytes explains the reactivity with K14 mono-
clonal antibodies and the reappearance of semifunctional inter-
mediate ®laments. In fact, the disease was altered from homozygous
REBS to hemizygous EBS with expression of aberrant K14
polypeptides, which even might have resulted in dominant-
negative EBS if wild-type K14 polypeptides had been coexpressed.
The dispersion of K14-positive cells was not diffuse, but
clustered, both in skin and in cultured cells. Therefore, the
presence of the in-frame transcript is most likely not due to either a
random or an environmental factor, but to an endogenous factor,
most likely a second somatic modulating factor in the genome that
affects the processing of the mutant KRT14 pre-mRNA. Further
research will be necessary to elucidate the molecular mechanism
underlying the reversion described here.
Patient keratinocytes also contained a pseudogene transcript.
This K14 pseudogene originated from the functional KRT14 gene
during human evolution (Savtchenko et al, 1988), and was
inactivated by three frame shifts in coding regions and three
mutations interfering with mRNA processing signals such as
intron/exon boundaries and the polyadenylation signal. In this
study, remarkably, transcription of the K14 pseudogene was
detected only in keratinocytes with a mutant KRT14 and not in
normal keratinocytes. An explanation is that the pseudogene was
upregulated in mutant and revertant keratinocytes. More likely is
Figure 4. Revertant keratinocytes re-expressed K14. Immunoblot
analysis of cell extracts of wild-type keratinocytes (lane C), keratinocytes
obtained from a K14-negative skin (lane A) and keratinocytes obtained
from a mosaic skin (lane B).




of chromosome 17 III-2a III-8a IV-30a VIIb IXb
D17S800 62.9 cM 1 1 1 1 1 1 1 1 1 1
D17S1814 61.5 cM 1 1 1 1 1 1 1 1 1 2
D17S1851 61.0 cM 1 1 1 1 1 1 1 2 1 2
aJonkman et al (1996).
bHut et al (2000).
Table II. Clonal cDNA analysis of KRT14
D10 bp Dexon 2 T®G, D6 pseudogen wild type
K14 mutant skin 5 (22)a 3 (13) 0 15 (65) 0
K14 revertant skin 2 (6) 0 9 (29) 20 (65) 0
normal human skin 0 0 0 0 25 (100)
aPercentage between brackets
Figure 5. A schematic drawing of the K14
protein and the amino acid changes resulting
from the revertant transcript. The striated
region in the protein concerns the deleted amino
acids 177 and 178 in the revertant protein. The
numbering indicates the codon numbers according
to Marchuk et al (1985).
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that the relative account of K14 pseudogene transcripts in the total
set of amplicons after K14 RNA reverse transcription±PCR is too
low to be noticed in normal cells, but its ratio increases in the
absence of wild-type transcripts in mutant and partial revertant
cells.
Revertant mosaicism was ®rst described in a type XVII collagen-
de®cient patient with generalized atrophic benign epidermolysis
bullosa who was compound heterozygous for COL17A1 null
mutations, and showed complete reversal of a mutant allele to a
normal sequence as the result of somatic gene conversion (Jonkman
et al, 1997). Partial revertant mosaicism has been reported in
another patient with generalized atrophic benign epidermolysis
bullosa, who was homozygous for a two-nucleotide deletion in
COL17A1 (Darling et al, 1999). In one allele the reading frame was
corrected by a downstream two-nucleotide insertion, thus this
mosaic was due to a second locus mutation. The patient expressed
aberrant type XVII collagen in a mosaic pattern, which did not
have any clinical effect on the skin. In the partial revertant mosaic
reported in this study the mosaicism is due to a third mechanism:
alteration of mRNA by in¯uencing the splicing process. The
mechanisms underlying revertant mosaicism give insight into
potential therapeutic intervention of genetic diseases.
We thank the patient for her collaboration. This study was supported by a grant from
DEBRA UK.
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